Healthcare Industry News: Vanguard
News Release - September 30, 2008
Vanguard Pharmaceutical Corporation Introduces New Company President
SAN ANTONIO, TX--(Healthcare Sales & Marketing Network)--Sep 30, 2008 -- Vanguard Pharmaceutical Corp. (Other OTC:VGPH.PK ), a company providing the market with affordable and safe generic medicines, has appointed Raul Fernandez as its new president. Mr. Fernandez has twelve years experience in the medical field. He has run three pulmonary rehab clinics in the Houston area and for the past six years has worked in healthcare administration."The position of President of Vanguard Pharmaceutical is an outstanding opportunity to lead a company with a promising future," said Mr. Fernandez. "I look forward to advancing our development in South America and believe my network and connections in Peru and Brazil will be an invaluable asset."
The Board of Directors at Vanguard is thrilled with Raul's experience and leadership. They would like to wish Francine Peres all the best as she relinquished her duties to allow for more personal family time.
www.Vanguardpharm.com
About Vanguard Pharmaceutical
In an era of ageing populations and rising health care costs. Vanguard's mission is to provide the market with drugs they can afford and with an assurance of its quality. To provide the market with affordable and safe drugs, Vanguard has focused on generic medicines. Generic medicines allow patients to access safe, effective, high-quality medicines at 10%-80% of the price of branded originator medicines. In this way, generic medicines support the sustainability of health care provision and contribute to controlling pharmaceutical expenditure.
Vanguard's main stream of business is the sale of generic drugs. It is currently targeting Latin America as it is believed to have a substantially unmet demand for advanced generics. The region is set to emerge as a globally significant market and its generics market is conservatively expected to reach US$6.4 billion by the year-end of 2009. Through its R&D facilities, Vanguard will strive to increase its generic product line further allowing them to penetrate Latin America and, in the future, expand into other geographic markets such as North America and Europe.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this release that are forward-looking statements are based on current expectations and assumptions that are subject to known and unknown risks, uncertainties, or other factors which may cause actual results, performance, or achievements of the company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Actual results could differ materially because of factors such as the effect of general economic and market conditions, entry into markets with vigorous competition, market acceptance of new products and services, continued acceptance of existing products and services, technological shifts, and delays in product development and related product release schedules, any of which may cause revenues and income to fall short of anticipated levels. All information in this release is as of the date of this release. The company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations.
Source: Vanguard Pharmaceuticals
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.
RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!